Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]
News [2550]
Articles [106]
Editorials [3]
Conferences [84]
elearning [20]
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...
Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )
25 Oct 2018
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...
Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )
25 Oct 2018
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic...
Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah )
25 Oct 2018
Cardiac events in stage III NSCLC treated in daily clinical practice
Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
Cardiac events in stage III NSCLC treated in daily clinical practice ( Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands )
25 Oct 2018
Ceritinib and ribociclib in ALK-positive NSCLC
Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...
Ceritinib and ribociclib in ALK-positive NSCLC ( Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
24 Oct 2018
Liquid biopsy as a monitoring tool for the benefit of chemotherapy...
Dr Laura Bonanno - University of Padova, Padova, Italy
Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC ( Dr Laura Bonanno - University of Padova, Padova, Italy )
24 Oct 2018
Therapeutic targeting at a pre-metastatic stage for brain metastases from lung...
Dr Sheila Singh - McMaster University, Ontario, Canada
Therapeutic targeting at a pre-metastatic stage for brain metastases from lung cancer ( Dr Sheila Singh - McMaster University, Ontario, Canada )
22 Oct 2018
SPLENDOUR: Added denosumab in first line adv NSCLC treatment
Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...
SPLENDOUR: Added denosumab in first line adv NSCLC treatment ( Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
22 Oct 2018
IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy
Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
22 Oct 2018
ESMO 2018: Highlights
Prof Gordon McVie , Will Davies
ESMO 2018: Highlights ( Prof Gordon McVie , Will Davies )
22 Oct 2018
Advances in metastatic non small cell lung cancer
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Advances in metastatic non small cell lung cancer ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
21 Oct 2018
KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC
Dr Roy S. Herbst - Yale Cancer Centre, New Haven, USA
KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC ( Dr Roy S. Herbst - Yale Cancer Centre, New Haven, USA )
21 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation